Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Software detects schizophrenia

This article was originally published in Clinica

Executive Summary

A computer software for analysing brain images shows promise as an early tool for identifying schizophrenics, a Canadian study has shown. The system has the potential to detect sub-types of the condition and help doctors choose the optimal treatment.

You may also be interested in...



Henlius Partners With Mabxience On Trastuzumab

Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.

European Parliament To Vote On MDR Delay As Council Rectifies Critical Mistake

The EU is pulling out all the stops to have the one-year delay to the MDR adopted before it is too late, and a crucial vote will take place on 16 April.

Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start

As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.

Topics

UsernamePublicRestriction

Register

MT070072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel